For instance, Venetoclax (ABT-199), the first commercially available selective BCL-2 inhibitor, is primarily approved for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) (8, 9). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.